Mirum Sets Oct. 12 Investor Call for Phase 3 EXPAND Data on LIVMARLI
Mirum Pharmaceuticals said it will hold an investor call on October 12, 2026, to report topline results from the Phase 3 EXPAND trial. The study is testing LIVMARLI (maralixibat) in patients aged 6 months and older with cholestatic pruritus tied to ultra-rare cholestatic liver diseases, including biliary atresia. The call is scheduled for 8:30 a.m. ET and will be webcast, with a replay available.
Mirum, based in Foster City, California, is a rare-disease drugmaker whose marketed medicines include LIVMARLI for Alagille syndrome and PFIC, plus therapies for FOP, bile-acid synthesis disorders, and CTX. Its pipeline also lists volixibat, brelovitug, and MRM-3379. The upcoming call concerns Phase 3 EXPAND, which is assessing maralixibat in cholestatic pruritus among patients six months and older with ultra-rare cholestatic liver conditions, biliary atresia included.
The company scheduled the webcast for 8:30 a.m. Eastern, with dial-in options and an archived replay through its investor site. Cholestatic pruritus is described as severe itching from impaired bile flow, a symptom that can influence treatment demand and trial endpoints.
If EXPAND results are favorable, they may inform future options for families coping with severe itching and rare liver disease, including infants and young children. Clinicians and caregivers could gain another data point for treatment discussions, while investors may reassess Mirum's pipeline prospects. Negative or mixed findings could temper expectations and delay potential broader use. The call itself mainly affects patients, caregivers, clinicians, and shareholders; broader society may feel indirect effects through rare-disease research priorities.